Literature DB >> 2996798

On the search for new anticancer drugs 14: the plasma pharmacokinetics and tissue distribution of spin-labeled thio-TEPA (SL-O-TT).

P L Gutierrez, B E Cohen, G Sosnovsky, T A Davis, M J Egorin.   

Abstract

We defined the plasma and tissue concentrations and pharmacokinetics of SL-O-TT, a spin-labeled analog of thio-TEPA, in 35-44-g male Swiss Webster mice that had received spin-labeled thio-TEPA at a dosage of 10 mg/kg. Concentrations of spin-labeled thio-TEPA in ethyl acetate extracts of tissue and plasma were determined by gas-liquid chromatography and electron spin resonance spectroscopy. Plasma concentrations of spin-labeled thio-TEPA declined in a biexponential fashion that was well described by the equation: Ct = 21.5e-0.276t + 2.30e-0.026t indicating a half-life alpha of 2.5 min and a half-life beta of 26.6 min. After 2 h there was still spin-labeled thio-TE-PA in plasma, but not in tissues. In tissues, no spin-labeled thio-TEPA was detected with gas-liquid chromatography 15 min after injection, but with electron-spin resonance label was found in lung and skeletal muscle. The main metabolite of spin-labeled thio-TEPA is spin-labeled TEPA, where oxidative desulfurization is invoked as the main metabolic mechanism. Reduction of the spin label to the hydroxylamine was also observed with time.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2996798     DOI: 10.1007/bf00263883

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  13 in total

1.  [ANTI-TUMOR ACTIVITY OF FREE STABLE RADICALS].

Authors:  N P KONOVALOVA; G N BOGDANOV; V B MILLER; M B NEIMAN; E G ROZANTSEV; N M EMANUEL
Journal:  Dokl Akad Nauk SSSR       Date:  1964-06-21

2.  Metabolic studies of 32P-labelled triethylenethiophosphoramide.

Authors:  A W CRAIG; B W FOX; H JACKSON
Journal:  Biochem Pharmacol       Date:  1959-12       Impact factor: 5.858

3.  Thiotepa in the treatment of tumours of the bladder.

Authors:  H C JONES; J SWINNEY
Journal:  Lancet       Date:  1961-09-16       Impact factor: 79.321

4.  The effects of topical THIOTEPA on the recurrence rate of superficial bladder cancers.

Authors:  J E Drew; V F Marshall
Journal:  J Urol       Date:  1968-06       Impact factor: 7.450

5.  Thiotepa bladder instillations: therapy and prophylaxis for superficial bladder tumors.

Authors:  R J Veenema; A L Dean; A C Uson; M Roberts; F Longo
Journal:  J Urol       Date:  1969-05       Impact factor: 7.450

6.  One-day VATH (vinblastine, Adriamycin, thiotepa, and Halotestin) therapy for advanced breast cancer refractory to chemotherapy.

Authors:  R D Hart; M Perloff; J F Holland
Journal:  Cancer       Date:  1981-10-01       Impact factor: 6.860

7.  Treatment of malignant meningeal disease with intrathecal thioTEPA: a phase II study.

Authors:  P H Gutin; J A Levi; P H Wiernik; M D Walker
Journal:  Cancer Treat Rep       Date:  1977-08

8.  Vinblastine, adriamycin, thiotepa, and halotestin (VATH): therapy for advanced breast cancer refractory to prior chemotherapy.

Authors:  M Perloff; R D Hart; J F Holland
Journal:  Cancer       Date:  1978-12       Impact factor: 6.860

9.  Toxicity, antitumor activity, and pharmacokinetics of spin-labeled thioTEPA analogs.

Authors:  N M Emanuel; N P Konovalova; R F Djachkovskaya
Journal:  Cancer Treat Rep       Date:  1976-11

10.  Plasma pharmacokinetics and tissue distribution of thiotepa in mice.

Authors:  M J Egorin; S R Akman; P L Gutierrez
Journal:  Cancer Treat Rep       Date:  1984-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.